Research programme: thyroid hormone receptor agonists - Karo PharmaAlternative Names: Research programme: glaucoma therapeutics - Karo Pharma
Latest Information Update: 21 Dec 2016
At a glance
- Originator Karo Bio
- Mechanism of Action Thyroid hormone receptor agonists
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Glaucoma
Most Recent Events
- 12 Sep 2006 Discontinued - Preclinical for Glaucoma in Sweden (Ophthalmic)
- 31 Dec 2001 SIFI have signed a one-year agreement with Karo Bio
- 07 May 2001 Karo Bio's thyroid hormone receptor agonist eye drops are available for licensing